Department of Microbiology and Immunology, and Center for Molecular Therapeutics and Resistance, Center for Sexually Transmitted Disease, Institute for Molecular Medicine and Infectious Disease, Drexel University College of Medicine, Philadelphia, PA 19102, USA.
Virol J. 2012 Jan 26;9:33. doi: 10.1186/1743-422X-9-33.
Continued efforts are being directed toward the development of microbicides that will be used to reduce or eliminate the risk of HIV-1 sexual transmission. Unfortunately, clinical trials involving polyanion-containing microbicide formulations, including Carraguard (λ-carrageenan [LC]) and Ushercell (cellulose sulfate [CS]) demonstrated that these products were ineffective and may have, in some circumstances, increased the risk of HIV-1 infection. These findings prompted reassessments of the in vitro activities of these agents to determine whether variables that can affect agent safety and efficacy had been overlooked during preclinical testing. One such variable is product retention and loss following topical application.
In the present studies involving an HIV-1-susceptible cell line and primary human immune cells, product loss was mimicked by introducing and then removing polyanionic compounds prior to HIV-1 infection. In these in vitro "washout" experiments, LC and CS significantly enhanced HIV-1 infection, despite potent antiviral activity when introduced simultaneously with the virus. The presence and magnitude of this effect were dependent on compound identity and concentration; target cell; interval between compound removal and virus challenge; and coreceptor usage. Levels of enhancement (relative to controls) were considerable, exceeding a 200% increase (CS) in P4-R5 MAGI cells and a 300% increase (LC) in human peripheral blood mononuclear cells.
These studies, which demonstrate significant increases in HIV-1 infection subsequent to application and removal of LC and CS, support plausible explanations for the failures of microbicides formulated from these compounds. Detailed studies are now underway to determine the mechanism responsible for this enhancement effect and to assess the potential contribution of this effect to the clinical failures of these agents.
人们正在继续努力开发杀微生物剂,以降低或消除 HIV-1 性传播的风险。不幸的是,含有多阴离子的杀微生物剂制剂(包括 Carraguard(λ-角叉菜胶 [LC])和 Ushercell(硫酸纤维素 [CS]))的临床试验表明,这些产品无效,并且在某些情况下可能增加了 HIV-1 感染的风险。这些发现促使人们重新评估这些试剂的体外活性,以确定在临床前测试中是否忽略了可能影响试剂安全性和有效性的变量。其中一个变量是局部应用后产品的保留和损失。
在本研究中,涉及对 HIV-1 敏感的细胞系和原代人免疫细胞,通过在 HIV-1 感染之前引入和去除多阴离子化合物来模拟产品损失。在这些体外“冲洗”实验中,LC 和 CS 尽管在同时引入病毒时具有有效的抗病毒活性,但显著增强了 HIV-1 感染。这种效应的存在和程度取决于化合物的特性和浓度;靶细胞;化合物去除和病毒攻击之间的间隔;以及共受体的使用。增强的程度(相对于对照)相当大,超过 P4-R5 MAGI 细胞中 200%(CS)和人外周血单核细胞中 300%(LC)的增加。
这些研究表明,在应用和去除 LC 和 CS 后,HIV-1 感染显著增加,这为这些化合物制成的杀微生物剂的失败提供了合理的解释。目前正在进行详细研究以确定导致这种增强效应的机制,并评估该效应对这些试剂临床失败的潜在贡献。